CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite BioPharma CANF shares soared 20.4% on Wednesday after the company reported positive top-line results from a mid-stage study of its investigational candidate, namodenoson, in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had progressed following prior systemic therapies.

Can-Fite’s namodenoson is a highly selective A3AR agonist, which has previously demonstrated a strong safety profile and anti-tumor activity in preclinical models of pancreatic cancer.

More on CANF’s Mid-stage Pancreatic Cancer Study Results

Can-Fite’s phase IIa study of namodenoson enrolled 20 patients with advanced PDAC who had received at least one prior line of therapy, representing a high-risk group with varying performance status and advanced metastatic disease.

Per the data readout, the mid-stage study met its primary safety endpoint, with namodenoson demonstrating strong tolerability in a heavily pretreated population of PDAC patients. No new safety concerns were reported during the study, and the observed safety profile remained consistent with prior clinical findings for the drug candidate across other oncology indications.

In the past six months, Can-Fite shares have plunged 54% compared with the industry’s 9% decline.

Beyond safety, the study also evaluated key secondary endpoints, including overall survival and progression-free survival. Survival monitoring is ongoing, and at the time of the data cut-off, roughly one-third of the enrolled patients were still alive. Continued follow-up is expected to provide a clearer picture of long-term survival outcomes.

As additional data matures, the company plans to share updated survival findings at upcoming scientific conferences. The encouraging safety profile in this difficult-to-treat patient group supports further clinical evaluation of namodenoson in pancreatic cancer. The candidate enjoys the FDA’s Orphan Drug designation in the United States for the treatment of pancreatic cancer.

Apart from PDAC, Can-Fite is also simultaneously evaluating namodenoson in a late-stage study for advanced liver cancer (hepatocellular carcinoma) and in a mid-stage study for metabolic-associated steatohepatitis.

Can-Fite’s clinical pipeline also comprises its lead candidate, piclidenoson, which is currently being evaluated in a pivotal late-stage study for the treatment of psoriasis.

Can-Fite Biopharma Ltd Price and Consensus

Can-Fite Biopharma Ltd price-consensus-chart | Can-Fite Biopharma Ltd Quote

CANF’s Zacks Rank and Stocks to Consider

Can-Fite currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are USANA Health Sciences USNA, Catalyst Pharmaceuticals CPRX and ALX Oncology Holdings ALXO. While USNA and CPRX sport a Zacks Rank #1 (Strong Buy) each, ALXO carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for USANA Health Sciences’ 2026 earnings per share (EPS) have risen from $1.90 to $2.00. USNA shares have lost 37.5% over the past six months.

USANA Health Sciences’ earnings beat estimates in three of the trailing four quarters and matched once, with the average surprise being 21.92%.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have risen from $2.54 to $2.82. CPRX shares have soared 22.9% over the past six months.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Over the past 60 days, estimates for ALX Oncology Holdings’ 2026 loss per share have narrowed from $1.21 to 88 cents. ALXO shares have rallied 97.3% over the past six months.

ALX Oncology Holdings’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 12.82%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research